5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data

BACKGROUND: Chemoprotective effect of 5-alpha reductase inhibitors (5-ARi) on bladder cancer (BCa) risk in men with Benign Prostatic Hyperplasia (BPH) has been explored with conflicting results. We sought to examine the effect of 5-ARi on new BCa diagnoses in a large US database. METHODS: Men ≥ 50 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Francesco, Belladelli, Federico, Glover, Frank, Basran, Satvir, Li, Shufeng, Mulloy, Evan, Pradere, Benjamin, Soria, Francesco, Krajewski, Wojciech, Nair, Rajesh, Muncey, Wade, Seranio, Nicolas, Eisenberg, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582125/
https://www.ncbi.nlm.nih.gov/pubmed/37548746
http://dx.doi.org/10.1007/s00345-023-04551-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582125/
https://www.ncbi.nlm.nih.gov/pubmed/37548746
http://dx.doi.org/10.1007/s00345-023-04551-4

Ejemplares similares